AbbVie Header AbbVie Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Expanding Access to Women\u2019s Health Fresenius Kabi Launches Generic Fertility Treatment","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"SWEDEN","productType":"Peptide","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lupin launches Ganirelix Acetate Injection in US","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Ganirelix

    Menu

    Ganirelix

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    MARKET PLACE

    PATENTS

    REF. STANDARDS & IMPURITIES

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Lupin Ltd

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lupin launches Ganirelix Acetate Injection in US

              Details:

              Ganirelix Acetate-Generic is a synthetic decapeptide with high antagonistic 6 activity against naturally occurring GnRH. It is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.

              Lead Product(s): Ganirelix

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Ganirelix Acetate-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 15, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Fresenius Kabi AB Brunna

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Expanding Access to Women’s Health Fresenius Kabi Launches Generic Fertility Treatment

              Details:

              Ganirelix Acetate Injection is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.

              Lead Product(s): Ganirelix

              Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Antagonä-Generic

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Aspen Ganirelix
              Skyepharma, an Expert and Innovative CDMO Partner for tailor-made solutions in complex oral solids and bioproduction.
              Close
              4
              Post Enquiry
              POST ENQUIRY